GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Replek AD (XMAE:REPL) » Definitions » Gross Profit

Replek AD (XMAE:REPL) Gross Profit : MKD291 Mil (TTM As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Replek AD Gross Profit?

Replek AD's gross profit for the three months ended in Dec. 2024 was MKD339 Mil. Replek AD's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was MKD291 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Replek AD's gross profit for the three months ended in Dec. 2024 was MKD339 Mil. Replek AD's Revenue for the three months ended in Dec. 2024 was MKD622 Mil. Therefore, Replek AD's Gross Margin % for the quarter that ended in Dec. 2024 was 54.48%.

Replek AD had a gross margin of 54.48% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Replek AD was 49.99%. The lowest was 24.06%. And the median was 44.93%.

Warning Sign:

Replek AD gross margin has been in long-term decline. The average rate of decline per year is -12.8%.


Replek AD Gross Profit Historical Data

The historical data trend for Replek AD's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Replek AD Gross Profit Chart

Replek AD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 570.34 607.68 591.09 418.68 468.77

Replek AD Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -106.79 388.22 - -47.25 338.60

Competitive Comparison of Replek AD's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Replek AD's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Replek AD's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Replek AD's Gross Profit distribution charts can be found below:

* The bar in red indicates where Replek AD's Gross Profit falls into.


;
;

Replek AD Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Replek AD's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=1948.035 - 1479.264
=469

Replek AD's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=621.505 - 282.908
=339

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MKD291 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Replek AD's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=339 / 621.505
=54.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Replek AD  (XMAE:REPL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Replek AD had a gross margin of 54.48% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Replek AD Gross Profit Related Terms

Thank you for viewing the detailed overview of Replek AD's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Replek AD Business Description

Traded in Other Exchanges
N/A
Address
Kozle 188, Skopje, MKD
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.